[go: up one dir, main page]

WO2007032748A1 - Procede de detection de la methylation de l'adn - Google Patents

Procede de detection de la methylation de l'adn Download PDF

Info

Publication number
WO2007032748A1
WO2007032748A1 PCT/SG2006/000271 SG2006000271W WO2007032748A1 WO 2007032748 A1 WO2007032748 A1 WO 2007032748A1 SG 2006000271 W SG2006000271 W SG 2006000271W WO 2007032748 A1 WO2007032748 A1 WO 2007032748A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
biotin
primer
primer set
methylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2006/000271
Other languages
English (en)
Inventor
Masafumi Inoue
Kok Keong Lee
Hiroshi Ida
Yoshiaki Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of WO2007032748A1 publication Critical patent/WO2007032748A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Definitions

  • the invention relates to a method for detecting methylation in DNA samples.
  • the invention relates to a method for detecting aberrant methylation of cytosine in CpG islands of tumour suppressor genes.
  • the invention also relates to the diagnosis of cancer.
  • Cancer is a major killer. Although in recent years the understanding of cancer has greatly improved, new and improved methods of early detection are still desirable.
  • DNA methylation is the addition of methyl groups ( -CH3) to cytosine (and sometimes adenine bases) in DNA. It occurs naturally and is thought to have a role in suppressing gene expression. As such, DNA methylation on tumour suppressor genes is often associated with cancer.
  • E- cadherin Genes such as E- cadherin, p16, p15 and RUNX3 are good examples for this methylation.
  • the p16 gene is a tumor suppressor gene and its methylation is associated with cancers. Since methylcytosine was found in genomic DNA, this epigenetic alteration has gained wide attention, especially because of its relation to gene silencing in disease leading to cancer.
  • methylcytosine is mainly found in cytosine-guanine (CpG) dinucleotides.
  • CpG cytosine-guanine
  • primers are used, which hybridize either only to a sequence that is formed by the bisulfite treatment of a DNA that is not methylated at the respective position, or, vice versa, primers, which only bind to a nucleic acid which has formed by the bisulfite treatment of a DNA that is methylated at the respective position.
  • amplified products can then be produced, whose detection in turn supplies hints of the presence of a methylated or unmethylated position in the sample, to which the primers bind.
  • the resulting products remain unclear whether this product is the specific products or not.
  • a method for detecting methylation in a DNA sample comprising the steps of:
  • the chemically converted DNA is amplified using a polymerase and a pair of oligonucleotide primers comprising an upper primer and a corresponding lower primer. More preferably, the upper primer carries the detectable label.
  • the agent chemically converts unmethylated cytosine residues in the DNA sample to uracil.
  • the oligonucleotide probe is bonded to a solid phase. More preferably, the solid phase a bead in a bead-array flow cytometry. Still more preferably, the reaction mix contains a plurality of beads, each bead has a different oligonucleotide probe to capture different target regions on the amplified DNA.
  • each bead has a different signature. More preferably that signature is a fluorescence wavelength such that each individual bead with a separate probe is distinguishable from other beads with different probes.
  • the label which is carried by the oligonucleotide primer is biotin and the further step of adding streptavidin wherein detecting the presence or absence of biotin is achieved by detecting a signal resulting from the interaction between biotin and streptavidin. More preferably, the added streptavidin is conjugated with a fluorescent label.
  • the amplification of the chemically converted DNA is carried out by means of a polymerase chain reaction. More preferably, the amplification comprises a multiplicity of oligonucleotide primers capable of simultaneously amplifying a plurality of genes of the DNA under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • the genes that are amplified may be selected from the group RUNX3, p16, RASSF1A, E-cadherin and hMLHl .
  • the agent that chemically converts the DNA is a bisulfite solution.
  • the polymerase that amplifies the chemically converted DNA is a heat- resistant DNA polymerase.
  • the methylation status of genes selected from the group RUNX3, p16, RASSF1A, E-cadherin and hMLHl in the DNA sample is determined in a single run.
  • a primer set comprising at least two primers capable of amplifying a portion of the sequence of p16 gene.
  • the primer set having the nucleotide sequence 5'-Biotin- GTTATTAGAGGGTGGGGCGGATCG-3' / 5'-AACGCCCCCGCCTCCAACAACG-3'.
  • a primer set comprising a multiplicity of primers capable of simultaneously amplifying a plurality of a portion of the p16 gene under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • a primer set comprising at least two primers capable of amplifying a portion of the sequence of RUNX3 gene.
  • the primer set having the nucleotide sequence 5'-(Biotin)- GGGATAGTTACGAGGGGCGGTCGTAC-3' / 5'- GACCGACGCGAACGCCTCCT -3'.
  • a primer set comprising a multiplicity of primers capable of simultaneously amplifying a plurality of a portion of the RUNX3 gene under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • a primer set comprising at least two primers capable of amplifying the promoter sequence of RASSF1A gene.
  • the primer set having the nucleotide sequence 5'-(Biotin)- TTTGCGAGAGCGCGTTTAG-3' / 5'-TAACAAACGCGAACCGAAC-3' or 5'- TTTGCGAGAGCGCGTTTAG-3' / 5'-(BiOtJn)-TAACAAACGCGAACCGAAC-3'.
  • a primer set comprising a multiplicity of primers capable of simultaneously amplifying a plurality of a portion of the RASSF1A gene under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • a primer set comprising at least two primers capable of amplifying the promoter sequence of E- cadherin gene.
  • the primer set having the nucleotide sequence 5'-(Biotin)- AGGTTAGAGGGTTATCGCGTTTAT-3' / 5'-TACTTTACAATTCCGACGCCACT-3' or, 5'- AGGTTAGAGGGTTATCGCGTTTAT-3' / 5'-(Biotin)-TACTTTACAATTCCGACGCCACT- 3' or, 5'-(Biotin)-AGGTTAGAGGGTTATCGCGTTTATGC-3' / 5'-
  • a primer set comprising a multiplicity of primers capable of simultaneously amplifying a plurality of a portion of the E-cadherin gene under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • a primer set comprising at least two primers capable of amplifying the promoter sequence of hMLH1 gene.
  • the primer set having the nucleotide sequence 5'-(Biotin)- ATTAATAGGAAGAGCGGATAGC-3' / 5'-CCTTCAACTATAACTTACGCCATC-3'.
  • a primer set comprising a multiplicity of primers capable of simultaneously amplifying a plurality of a portion of the hMLH1 gene under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • a primer set comprising a multiplicity of primers capable of simultaneously amplifying a plurality of genes selected from RUNX3, p16, RASSF1A, E-cadherin and hMLH1 under a single set of reaction conditions in a multiplex polymerase chain reaction.
  • an oligonucleotide probe having a nucleotide sequence that hybridizes under stringent conditions to the complement of DNA sequences of RUNX3 and/or p16 and/or
  • the probes having the nucleotide sequences of:
  • CT 5'-H2N-C6-gggaggCgttgaagtTggggt-3';
  • TC 5'-H2N-C6-gggaggTgttgaagtCggggt-3';
  • CT 5'-H2N-C6-gggCggtgttttTggggttt-3';
  • a set of four probes are needed to detect the four methylation states in one reaction.
  • the four methylation states are: 1 all the cytosines are methylated; 2 only the first cytosine is methylated; 3 the second cytosine is methylated and; 4 where none of the cytosines are methylated. It is possible that more than 2 cytosine residues may be detected in which case there may be more that 4 DNA methylation states detected in one reaction.
  • the methylation states of more that one cancer suppressor gene can be measured in one reaction. This takes less time than traditional DNA methylation detection.
  • a fourteenth aspect of the invention there is provided a method of aiding assessment of a patient's risk of developing cancer, or progression of cancer, the method comprising the step of obtaining a sample containing nucleic acid from a patient and carrying out the method according to the first preferred aspect of the invention.
  • a method of diagnosing or assessing a patient's risk of developing cancer or other diseases by detecting DNA methylation in genes selected from the group RUNX3, p16, RASSF1A, E- cadherin and hMLH1, by carrying out the method according to the first preferred aspect of the invention.
  • a kit of parts comprising:
  • the kit further comprises a bisulfite agent.
  • the label which is carried by the oligonucleotide primer is biotin and the further step of adding streptavidin wherein detecting the presence or absence of biotin is achieved by detecting a signal resulting from the interaction between biotin and streptavidin. More preferably, the added streptavidin is conjugated with a fluorescent label.
  • the means of detecting the label is fluorescent flow cytometry. More preferably, fluorescence is detected after irradiation with two light sources the first allowing identification of the florescence signature of the bead and the specific probe indicating the possible DNA methylation state; and the second to detect hybridisation of a sample to that probe so the amount of sample in that methylation state can be calculated.
  • there are four methylation states 1 where all the cytosines are methylated, 2 where only the first cytosine is methylated, 3 where the second cytosine is methylated and 4 where none of the cytosines are methylated. It is possible that more than 2 cytosine residues may be detected in which case there may be more that 4 DNA methylation states detected in one reaction.
  • DNA methylation it is meant the addition of a methyl group to the carbon-5 position of cytosine residues, is the only common covalent modification of human DNA and occurs almost exclusively at cytosines that are followed immediately by a guanine (so- called CpG dinucleotides).
  • CpG dinucleotides a guanine
  • the bulk of the genome displays a clear depletion of CpG dinucleotides, and those that are present are nearly always methylated.
  • small stretches of DNA known as CpG islands, are comparatively rich in CpG nucleotides and are nearly always free of methylation.
  • CpG islands are frequently located within the promoter regions of human genes, and methylation within the islands has been shown to be associated with transcriptional inactivation of the corresponding gene. Alterations in DNA methylation might be pivotal in the development of most cancers. In recent years, it has become apparent that the pattern of DNA methylation observed in cancer generally shows a dramatic shift compared with that of normal tissue. Although cancers often exhibit clear reductions throughout their genomes in the levels of DNA methylation, this goes hand-in-hand with increased methylation at the CpG islands. Such changes in methylation have a central role in tumourigenesis; in particular, methylation of CpG islands has been shown to be important in transcriptional repression of numerous genes that function to prevent tumour growth or development. Studies of DNA methylation in cancer have thus opened up new opportunities for diagnosis, prognosis and ultimately treatment of human tumours.
  • the nucleic acid in the DNA sample is first chemically converted with bisulfite solution.
  • the solution is sodium bisulfate and it converts unmethylated cytosine to uracil. Methylated cytosine residues, on the other hand, would remain unchanged. Comparison of sodium bisulfate treated and untreated DNA reveal methylated cytosines.
  • the DNA samples may be obtained from a patient's cell lines, blood, sputum, stool, urine, serum, cerebrospinal fluid, tissue embedded in paraffin, for example, tissue from intestine, kidney, brain, heart, prostate, lung, eyes, breast or liver, histological slides and all possible combinations thereof.
  • a technique is also known as Methylation Specific PCR (MSP) which is a PCR technique for the study of DNA CpG methylation.
  • MSP Methylation Specific PCR
  • primers are used, which hybridize either only to a sequence that forms by the bisulfite treatment of a DNA which is unmethylated at the respective position, or, vice versa, primers which bind only to a nucleic acid which forms by the bisulfite treatment of a DNA which is methylated at the respective position.
  • the amplified DNA or amplicons can be produced accordingly with these primers.
  • Standard PCR has been described in US Patent Nos. 4,683,195; 4,800,195; and 4,965,188.
  • Primers are generally artificially synthesized, but they may be of recombinant origin or, in some applications, a mixture of both. They generally are used in pairs and comprise two nucleic acid sequences, one with a sense orientation (5'to 3') and one with an antisense (3'to 5'). They are generally used under optimized conditions for the purpose of identifying a specific gene or for diagnostic use.
  • oligonucleotide pairs may be used under less stringent or optimized conditions for identification and/or quantitation of closely related DNA or RNA sequences.
  • PCR-based techniques include (1) Inverse PCR, which is the first method to report successful acquisition of unknown sequences starting with primers based on a known region (Triglia, T. et al (1988) Nucleic Acids Res 16: 8186); (2) Capture PCR (Lagerstrom M. et al (1991) PCR Methods Applic 1 : 111-19) which is a method for PCR amplification of DNA fragments adjacent to a known sequence in human and YAC DNA; (3) targeted gene walking (Parker J. D.
  • Primers developed according to the method of the present invention are added to a PCR assay in an amount effective for amplifying any target nucleic acid present in the sample. At least about 5 picomoles (moles) of each primer species may be used in a PCR reaction. It is known to use between 5 and 10 pmoles of primer per 50 ul PCR reaction, for optimum amplification (Perkin Elmer). At the minimum of 5 pmoles per species, a primer with 4 mixed base positions would have 5pm X 16 species, for a total of 80 pm. If both primers in the PCR reaction have 4 mixed positions, there would be a total of 2 X 80 pm, for a total of 160 pm of primers in a 50 microliter reaction. PCR and the resulting detection of PCR products are accomplished by methods known in the art.
  • primer it is meant to refer to an oligonucleotide, whether natural or synthetic, capable of acting as a point of initiation of DNA synthesis under conditions in which synthesis of a primer extension product complementary to a nucleic acid strand is induced, i. e., in the presence of four different nucleoside triphosphatase and an agent for polymerization (i. e., DNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature.
  • a primer is preferably a single-stranded oligodeoxynucleotide. The appropriate length of a primer depends on the intended use of the primer but typically ranges from about 17 to about 23 nucleotides.
  • Primers generally require cooler temperatures to form sufficiently stable hybrid complexes with the template.
  • a primer need not reflect the exact sequence of the template nucleic acid, but must be sufficiently complementary to hybridize with the template.
  • Primers can incorporate additional features which allow for the detection or immobilization of the primer but do not alter the basic property of the primer (i. e., acting as a point of initiation of DNA synthesis).
  • primers may contain an additional nucleic acid sequence at the 5'end which does not hybridize to the target nucleic acid, but which facilitates cloning of the amplified product.
  • primers for use in processes such as PCR.
  • Various techniques for synthesizing oligonucleotide primers are well known in the art, including phosphotriester and phosphodiester synthesis methods.
  • the primers could at least 18-30, 40, 50, 100, 250 or 500 nucleotides in length.
  • DNA sequence or a portion or fragment thereof, entirely by synthetic chemistry using laboratory equipment familiar to the skilled artisans.
  • the source of information for producing the synthetic sequence may be derived from the known homologous sequence from closely related organisms. After synthesis, the nucleic acid sequence can be used alone or joined with another known sequence and inserted into one of the many available DNA vectors and their respective host cells using techniques well known in the art.
  • synthetic chemistry may be used to introduce specific mutations into the nucleic acid sequence. Alternatively, a portion of sequence in which a mutation is desired can be synthesized and recombined with a portion of an existing genomic or recombinant sequence.
  • amplification it is meant to refer to an increase in the amount of the desired nucleic acid molecule present in a sample.
  • amplicon or “amplified DNA” it is meant to refer to a small DNA fragment which is the product of PCR or LCR; a piece of DNA that has been synthesized using amplification techniques.
  • each bead has a different signature. More preferably that signature is a fluorescence wavelength such that each individual bead with a separate probe is distinguishable from other beads with different probes.
  • hybridization it is meant to refer to the formation of a duplex structure by two single- stranded nucleic acids due to complementary base pairing. Hybridization can occur between fully complementary nucleic acid strands or between substantially complementary nucleic acid strands that contain minor regions of mismatch. Conditions under which only fully complementary nucleic acid strands will hybridize are referred to as “stringent hybridization conditions” or “sequence-specific hybridization conditions”. Stable duplexes of substantially complementary sequences can be achieved under less stringent hybridization conditions.
  • nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length and base pair concentration of the oligonucleotides, ionic strength, and incidence of mismatched base pairs, following the guidance provided by the art (see, e. g., Sambrook et al., Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y. (1985), Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wilty- Interscience, John Wiley and Sons, N. Y. (1987 updated quarterly) (each incorporated herein by reference).
  • hybridizes under stringent conditions it is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other.
  • the conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other.
  • stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N. Y. (1989), 6.3.1-6.3.6.
  • stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C , followed by one or more washes in 0.2. times. SSC, 0.1% SDS at 50-65°C. Examples of moderate to low stringency hybridization conditions are well known in the art.
  • DNA typically contains a polynucleotide composed of the 4 "natural" bases: A (adenine), T (thymine), C (cytosine), and G (guanine).
  • A adenine
  • T thymine
  • C cytosine
  • G guanine
  • the hydrogen bonding (or base pairing) among these nucleotides creates the double-stranded structure of a DNA molecule.
  • An A-containing residue base pairs to a T-containing residue through the formation of two hydrogen bonds; a G-containing residue base pairs to a C-containing residue through the formation of three hydrogen bonds.
  • target region and “target nucleic acid” it refers to a region of a nucleic acid which is to be amplified, detected, or otherwise analyzed.
  • Target nucleic acid capable of being amplified through use of the primers developed by the methods of the present invention includes any prokaryotic or eukaryotic nucleic acid (DNA or RNA), which can include any plant, animal, bacterial, viral, fungal, etc., nucleic acids for which at least one nucleic acid sequence is known.
  • the sequence to which a primer or probe hybridizes can be referred to as a "target sequence”.
  • probes it is meant to refer to nucleic acid sequences of variable length, preferably between at least about 10 and as many as about 6,000 nucleotides, depending on use. They are used in the detection of identical, similar, or complementary nucleic acid sequences in a particular cell or tissue or test sample. In the present invention, they are used to hybridise to complementary regions of the DNA that is amplified. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. They may be single-or double-stranded and carefully designed to have specificity in PCR, hybridization membrane-based, bead- array flow cytometry or ELISA-like technologies.
  • Oligonucleotides such as primers and probes, can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphotriester method of Narang et al.,
  • Bead-array is an array of DNA probes on beads in a capillary with an order determined by the probe species and hybridization is performed by the reciprocal flow of the sample.
  • Beads of 5.6- ⁇ m diameter are lined in a determined order in a capillary. Each bead can have a different DNA probe to capture different DNA targets. Each bead is conjugated with DNA probes, and can be identified by its order in the capillary. This probe array is easily produced by just arraying beads conjugated with probes into the capillary in a fixed order. The hybridization is also easily completed by introducing samples (1-300 ⁇ l) into the capillary with reciprocal flow.
  • DNA micro-array technology may be used.
  • DNA micro-array is an array of DNA probes that are respectively synthesized using either photolithographic techniques or liquid-spotting methods. It has been used for various applications including gene expression profiling and mutation detection. Although it is a very powerful and attractive device, it is very expensive and a practical fabrication method for producing a cost- effective device is still required. In addition, it is impossible to rearrange any of the probes in the array in accordance with changes in the analysis target. This requirement seems to be overcome by micro-spheres having DNA probes.
  • the bead-array is designed so as to decrease the volume of reaction space to ⁇ 0.1 ⁇ l to enable fast hybridization.
  • the bead size was determined to be 5.6 ⁇ m in diameter.
  • 1 to 100 beads or more may be placed in a capillary, which occupy ⁇ 1-cm length in the capillary.
  • the capillary is connected to a sample reservoir, buffer reservoir, waste reservoir and a syringe pump with capillary tubing.
  • the device is placed in a thermal chamber.
  • a sample solution including target DNAs tagged with the detectable label is introduced into the bead-array from the sample reservoir and continuously flowed reciprocally by operating the syringe pump.
  • the beads are washed with buffer solutions introduced from the buffer reservoirs.
  • the bead-array is illuminated by a light source and the fluorescence intensity of each bead is measured with a CCD camera.
  • detecting a signal it includes any optically detectable chromophoric or fluorescent signals that are associated with the functioning of the particular model system used.
  • signals will generally be produced by products of the enzyme's catalytic action, e.g., on a chromogenic or fluorogenic substrate.
  • binding systems e.g., receptor ligand interactions
  • signals will typically involve the association of a labelled ligand with the receptor, or vice versa.
  • labels it includes labels that are commonly detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
  • useful nucleic acid labels include 32P, 35S, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available.
  • Labelling agents include e.g., monoclonal antibodies, polyclonal antibodies, proteins, or other polymers such as affinity matrices, carbohydrates or lipids. Detection proceeds by any of a variety of known methods, including spectrophotometric or optical tracking of radioactive or fluorescent markers, or other methods which track a molecule based upon size, charge or affinity.
  • a detectable moiety can be of any material having a detectable physical or chemical property.
  • detectable labels have been well-developed in the field of gel electrophoresis, column chromatography, solid substrates, spectroscopic techniques, and the like, and in general, labels useful in such methods can be applied to the present invention.
  • a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical thermal, or chemical means.
  • Useful labels in the present invention include fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., 3H, 1251, 35S, 14C, 32P or 33P), enzymes (e.g., LacZ, CAT, horse radish peroxidase, alkaline phosphatase and others, commonly used as detectable enzymes, either as marker products or as in an ELISA), nucleic acid intercalators (e.g., ethidium bromide) and calorimetric labels such as colloidal gold or colored glass or plastic (e.g. polystyrene, polypropylene, latex, etc.) beads.
  • fluorescent dyes e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like
  • radiolabels e.g., 3H, 1251, 35S, 14C, 32P or 33P
  • Fluorescent labels are particularly preferred labels.
  • Preferred labels are typically characterized by one or more of the following: high sensitivity, high stability, low background, low environmental sensitivity and high specificity in labelling.
  • Fluorescent moieties which are incorporated into the labels of the invention, are generally are known, including 1- and 2-aminonaphthalene, p,p'-diaminostilbenes, pyrenes, quaternary phenanthridine salts, 9-aminoacridines, p,p'-diaminobenzophenone imines, anthracenes, oxacarbocyanine, merocyanine, 3-aminoequilenin, perylene, bis- benzoxazole, bis-p-oxazolyl benzene, 1 ,2-benzophenazin, retinol, bis-3-aminopyridinium salts, hellebrigenin, tetracycline, sterophenol, benzimidazolylphenylamine, 2-oxo-3- chromen, indole, xanthen, 7-hydroxycoumarin, phenoxazine, calicylate, strophanthidin
  • Individual fluorescent compounds which have functionalities for linking to an element desirably detected in an apparatus or assay of the invention, or which can be modified to incorporate such functionalities include, e.g., dansyl chloride; fluoresceins such as 3,6-dihydroxy-9-phenylxanthhydrol; rhodamineisothiocyanate; N-phenyl 1-amino-8-sulfonatonaphthaIene; N-phenyl 2-amino- 6-suIfonatonaphthalene; 4-acetamido-4-isothiocyanato-stilbene-2,2'-disulfonic acid; pyrene-3-sulfonic acid; 2-toluidinonaphthalene-6-sulfonate; N-phenyl-N-methyl-2- aminoaphthalene-6-sulfonate; ethidium bromide; stebrine; auromine-0,2-(9'- anthroyl)palmitate; dans
  • fluorescent tags are commercially available from SIGMA chemical company (Saint Louis, Mo.), Molecular Probes, R&D systems (Minneapolis, Minn.), Pharmacia LKB Biotechnology (Piscataway, N.J.), CLONTECH Laboratories, Inc. (Palo Alto, Calif.), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, Wis.), Glen Research, Inc., GIBCO BRL Life Technologies, Inc. (Gaithersberg, Md.), Fluka Chemica- Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), and Applied Biosystems (Foster City, Calif.) as well as other commercial sources known to one skilled.
  • fluorescent labels absorb light above about 300 nm, preferably about 350 nm, and more preferably above about 400 nm, usually emitting at wavelengths greater than about 10 nm higher than the wavelength of the light absorbed. It should be noted that the absorption and emission characteristics of the bound label may differ from the unbound label. Therefore, when referring to the various wavelength ranges and characteristics of the labels, it is intended to indicate the labels as employed and not the label which is unconjugated and characterized in an arbitrary solvent.
  • Fluorescent labels are one preferred class of detectable labels, in part because by irradiating a fluorescent label with light, one can obtain a plurality of emissions. Thus, a single label can provide for a plurality of measurable events.
  • Detectable signal may also be provided by chemiluminescent and bioluminescent sources.
  • Chemiluminescent sources include a compound which becomes electronically excited by a chemical reaction and may then emit light which serves as the detectible signal or donates energy to a fluorescent acceptor.
  • a diverse number of families of compounds have been found to provide chemiluminescence under a variety of conditions. One family of compounds is 2,3-dihydro-1,4-phthalazinedione. The most popular compound is luminol, which is a 5- amino compound.
  • Chemiluminescent analogs include para-dimethylamnino and -methoxy substituents. Chemiluminescence may also be obtained with oxalates, usually oxalyl active esters, e.g., p-nitrophenyl and a peroxide, e.g., hydrogen peroxide, under basic conditions. Other useful chemiluminescent compounds are also known and available, including -N-alkyl acridinum esters (basic H.sub.2 O.sub.2) and dioxetanes. Alternatively, luciferins may be used in conjunction with luciferase or lucigenins to provide bioluminescence.
  • the label may coupled directly or indirectly to a molecule to be detected (a product, substrate, enzyme, or the like) according to methods well known in the art.
  • a molecule to be detected a product, substrate, enzyme, or the like
  • Non radioactive labels are often attached by indirect means.
  • a ligand molecule e.g., biotin
  • the ligand then binds to an anti-ligand (e.g., streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound.
  • a number of ligands and anti-ligands can be used. Where a ligand has a natural anti- ligand, for example, biotin, thyroxine, and Cortisol, it can be used in conjunction with labeled, anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody. Labels can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases.
  • Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc.
  • Chemiluminescent compounds include luciferin, and 2,3- dihydrophthalazinediones, e.g., luminol.
  • Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography.
  • the label is a fluorescent label
  • it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence, e.g., by microscopy, visual inspection, via photographic film, by the use of electronic detectors such as digital cameras, charge coupled devices (CCDs) or photomultipliers and phototubes, and the like. Fluorescent labels and detection techniques, particularly microscopy and spectroscopy are preferred. Similarly, enzymatic labels are detected by providing appropriate substrates for the enzyme and detecting the resulting reaction product. Finally, simple calorimetric labels are often detected simply by observing the colour associated with the label. For example, conjugated gold often appears pink, while various conjugated beads appear the colour of the bead.
  • the status of methylation pattern of the gene is then determined by detection of the label fluorescent intensity in a bead-array flow cytometric assay.
  • the results obtained were compared with the results by both gel based MSP and bisulfite direct DNA sequencing.
  • the present method provides detection of aberrant DNA methylation in tumour suppressor genes in a high sensitive and yet specific manner.
  • the present method may be used to detect methylation of the genes RUNX3, p16, RASSF1A, E-cadherin and hMLHL Therefore, the following primers and probes may be used by the present method:
  • H2N denotes amino modifier for cross linking to the bead.
  • C6 denotes carbon spacer
  • RASSF1A S-Probe1CC 5'-H2N-C6-gggaggCgttgaagtCggggt-3'(Bead #17)
  • RASSF1A S-Probe1CT 5'-H2N-C6-gggaggCgttgaagtTggggt-3' (Bead #18)
  • RASSF1A S-Probe1TC 5'-H2N-C6-gggaggTgttgaagtCggggt-3' Bead #19)
  • RASSF1 A S-Probe1TT 5'-H2N-C6-gggaggTgttgaagtTggggt-3' (Bead #20)
  • Ecad S-Probe 1CC 5'-H2N-C6-gggCggtgttttCggggttt-3' (Bead #73)
  • Ecad S-Probe 1CT 5'-H2N-C6-gggCggtgttttTggggttt-3' (Bead #74)
  • Ecad S-Probe 1TC 5'-H2N-C6-gggTggtgtttttCggggttt-3' (Bead #75)
  • Ecad S-Probe 1TT 5'-H2N-C6-gggTggtgttttTggggttt-3' (Bead #76)
  • a method of aiding assessment of a patient's risk of developing cancer, or progression of cancer comprising the step of obtaining a sample containing nucleic acid from a patient and carrying out the method in accordance with the first preferred aspect of the invention. This may be carried out by detecting DNA methylation in any or all of the genes selected from the group RUNX3, p16, RASSF1A, E-cadherin and hMLH1.
  • the CpG islands in p16 and RUNX3 genes are as follows:
  • the cytosines in the CpG dinucleotides are generally unmethylated.
  • sequences (particularly promoter sequences) of genes associated with certain cancers or inherited diseases such as RUNX3, p16, RASSF1A, E-cadherin and hMLH1 , these cytosines can be methylated. Therefore, the method of the present invention can diagnose/assess a patient's risk of developing cancer or other diseases by detecting DNA methylation in those genes.
  • the primer/primers and probe/probes according to the invention may be provided as part of a kit, e. g. in a suitable container such as a vial in which the contents are protected from the external environment.
  • the kit may include instructions for use of the nucleic acid, e. g. in PCR and/or a method for determining the presence of nucleic acid of interest in a test sample such as the hybridisation technique described herein.
  • a kit wherein the nucleic acid is intended for use in PCR may include one or more other reagents required for the reaction, such as polymerase, nucleosides, buffer solution etc.
  • the nucleic acid may be labelled.
  • a kit for use in determining the presence or absence of nucleic acid of interest may include one or more articles and/or reagents for performance of the method, such as means for providing the test sample itself.
  • reagents for performance of the method such as means for providing the test sample itself.
  • the label carried on the primer is biotin
  • a further reagent including streptavidin may be added to detect the nucleic acid of interest.
  • the streptavidin may be conjugated with a fluorescent label.
  • the kit includes one or more primers for the determination of the presence of methylation of those genes.
  • Preferred primers are described as above.
  • Test samples were created by 10-fold serially diluting bisulfite-modified completely methylated DNA with bisulfite-modified completely unmethylated DNA and labeled as 100, 10, 1, 0.1 , 0.01, and 0.001. Sample 100 is thus 100% of completely methylated DNA and no completely unmethylated DNA. Sample 10 is 10% of completely methylated DNA and 90% completely unmethylated DNA and so forth.
  • the promoter region of p16 sequence was obtained from NCBI Locus AB060808. The sequence was then created by converting the original genomic sequence to bisulfite DNA sequence based on the principle in which all CpG's cytosines are methylated and thus remain as C ( Figure 1).
  • Primer set The methylation specific primers were selected.
  • the sense and antisense methylation specific primers for this experiment are as follows: Upper primer: IMCB B-p16M3-5S (699U24, C:2) : 5'-Biotin- GTTATTAGAGGGTGGGGCGGATCG-3' Lower primer.
  • IMCB p16M3-3AS (868L22, G:3): 5'- AACGCCCCCGCCTCCAACAACG-3'
  • the expected amplicon sizes created by this primer set is 191 bp.
  • PCR was performed using the QlAGEN HotStrart Taq PCR kit (catalog no. 210210).
  • PCR products made by the above primer set were analyzed by conventional agarose gel electrophoresis and ethidium bromide staining.
  • Luminex(R) 100 (TM) system TX, USA was used.
  • H2N denotes amino modifier for cross linking to the bead.
  • C6 denotes carbon spacer -
  • xMAP(Tm)-Carboxylated Microspheres were obtained from the supplier (Luminex(R), TX, USA). They are internally labeled with fluorescent dyes and contain surface carboxyl groups for covalent attachment of ligands (or biomolecules).
  • the -COOH on the surface on the bead and -NH2 of the oligo probe are cross linked by Carbodiimide coupling, according to the manufactures' protocol (Luminex(R), TX, USA). There are 100 kinds of beads are commercially available.
  • the number 151, 152, 153 and 154 were selected and bound with GG, AG, GA and AA probe respectively for p16 probes in this experiment.
  • 5 x 10(6) beads were reacted with 0.2 nmol of each probe by 0.04%(w/v) EDC [1-ethyl- 3(3-dimethylaminopropyl) carbodiimide HCI (Pierce #77149) in 0.1 M MES buffer [2-(N- Morpholino)ethanesulfonic acid Hydrate (Sigma M2933)] at pH 4.5.
  • the beads were counted by Luminex(R) 100 after the coupling step.
  • Step 1 Sample preparation
  • 5ul of the PCR product was hybridized in the presence of 5ul of the Beads mix and 40ul of 1x TMAC hybridization solution [3 M TMA (Sigma Cat. T-3411), 0.1% Sodium lauroyl Sarcosinate (Sigma Cat. L-5125), 50mM Tris-HCI, pH 8.0 (Sigma Cat. T3038), 4mM EDTA, pH 8.0 (Gibco Cat.15575-038)].
  • the mixture was denatured at 95°C for 10 minutes and incubated at 60°C for 40 minutes.
  • washing buffer [1x Phosphate Buffer Saline, 0.01% Tween 20 (Sigma Cat. P1379)] was added to each well at room temperature and centrifuged at 2000g for 10 minutes. The supernatant was decanted and another 100ul of washing buffer was added followed by incubation at 52°C for 10 minutes. The mixture was centrifuged at 2000g for 10 minutes and the supernatant was decanted.
  • Step 4 Signal production 70 ul of washing buffer (1x Phosphate Buffer Saline, 0.01% Tween 20) containing X1/500 Streptavidin, R-phycoerythrin conjugate (Molecular Probes, Cat. S866) was added and mixed by repeat pipetting. The mixture was incubated at 52°C for 5 minutes.
  • the fluorescent signal was read by Luminex 100.
  • Figures 6 to 8 shows the sensitivity and specificity of Beads-MSP in low and high stringent conditions in a methylation specific PCR using p16.
  • the detection of DNA methylation using bead-array platform is more specific robust than the conventional agarose electrophoresis and ethidium bromide.
  • Met-DNA detection using bead-array platform DNA is treated with bisulfite as discussed in Example 1.
  • RASSF1A Set 1 (Upper primer is biotinylated)
  • RASSF1A S-Probe1CC 5'-H2N-C6-gggaggCgttgaagtCggggt-3'(Bead #17)
  • RASSF1A S-Probe1CT 5'-H2N-C6-gggaggCgttgaagtTggggt-3' (Bead #18)
  • RASSF1A S-Probe1TC 5'-H2N-C6-gggaggTgttgaagtCggggt-3' Bead #19)
  • RASSF1A S-Probe1TT 5'-H2N-C6-gggaggTgttgaagtTggggt-3' (Bead #20)
  • Ecad S-Probe 1CC 5'-H2N-C6-gggCggtgttttCggggttt-3' (Bead #73)
  • Ecad S-Probe 1CT 5'-H2N-C6-gggCggtgttttTggggttt-3' (Bead #74)
  • Ecad S-Probe 1TC 5'-H2N-C6-gggTggtgttttCggggttt-3' (Bead #75)
  • Ecad S-Probe 1 TT 5'-H2N-C6-gggTggtgtttTggggttt-3' (Bead #76)
  • Multiplex PCR was performed using the QIAGEN Multiplex PCR kit (catalog no. 206143). 5ul of DNA, RUNX3 upper primer and lower primer at a final concentration of 0.1 uM and 0.05uM, p16 upper and lower primer at a final concentration of 0.1 uM and 0.1uM, RASSF1A upper and lower primer at a final concentration of 0.2uM and 0.1uM, E-cadherin upper and lower primer at a final concentration of 0.2uM and 0.1 uM, hMLH1 upper and lower primer at a final concentration of 0.2uM and 0.1 uM, and GAPDH upper and lower primer at a final concentration of 0.05uM and 0.025uM in 50uI final volume, on a Stratagene Robocycler 40 (La JoIIa, California) by using the following steps: initial denaturation at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 45 s, annealing at 58°
  • Example 1 Bead coupling for the probe is described in Example 1. The hybridisation and detection techniques are also carried out as described in Example 1.
  • Figure 9 shows graphically the results of simultaneous detection of DNA methylation in tumour suppressor genes by a bead-based flow cytometric assay.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés de détection de la méthylation dans des échantillons d'ADN, en particulier de la méthylation aberrante d'une cytosine dans les îles CpG de gènes suppresseurs de tumeur. Le procédé comprend: (a) le traitement de l'échantillon d'ADN par une solution de bisulfite afin de convertir la cytosine non méthylée en uracile; (b) l'amplification de l'ADN à l'aide d'amorces oligonucléotidiques portant un marqueur détectable; (c) l'hybridation de l'ADN amplifié à une sonde oligonucléotidique; (d) la détermination de la méthylation éventuelle de l'échantillon d'ADN par la détection de la présence ou de l'absence de marqueur dans l'ADN amplifié hybridé. L'invention concerne également des amorces et des sondes destinées à la mise en oeuvre du procédé.
PCT/SG2006/000271 2005-09-15 2006-09-15 Procede de detection de la methylation de l'adn Ceased WO2007032748A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71693405P 2005-09-15 2005-09-15
US60/716,934 2005-09-15

Publications (1)

Publication Number Publication Date
WO2007032748A1 true WO2007032748A1 (fr) 2007-03-22

Family

ID=37865235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2006/000271 Ceased WO2007032748A1 (fr) 2005-09-15 2006-09-15 Procede de detection de la methylation de l'adn

Country Status (1)

Country Link
WO (1) WO2007032748A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083046A3 (fr) * 2009-01-15 2010-12-02 The Salk Institute For Biological Studies Procédés ayant recours à un séquençage de nouvelle génération pour identifier les 5-méthylcytosines dans le génome
WO2011028533A3 (fr) * 2009-08-24 2011-06-09 Perkinelmer Health Sciences, Inc. Procédés de détection de méthylation d'adn à l'aide de particules codées
US20110287967A1 (en) * 2009-01-28 2011-11-24 Ait Austrian Institute Of Technology Gmbh Lung Cancer Methylation Markers
WO2014160117A1 (fr) 2013-03-14 2014-10-02 Abbott Molecular Inc. Systèmes et procédés d'amplification multiplexe spécifiques de la méthylation
WO2015101515A3 (fr) * 2013-12-31 2015-08-20 F. Hoffmann-La Roche Ag Procédés d'évaluation de la régulation épigénétique du fonctionnement du génome par l'intermédiaire du statut de méthylation de l'adn, ainsi que systèmes et kits associés
CN110923320A (zh) * 2019-12-26 2020-03-27 益善生物技术股份有限公司 用于检测肺癌相关基因甲基化的核酸组合物、试剂盒和检测方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014388A2 (fr) * 2001-08-09 2003-02-20 Epigenomics Ag Acides nucleiques d'analyse d'un cancer du colon et procede associe
WO2003052135A2 (fr) * 2001-12-14 2003-06-26 Epigenomics Ag Acides nucleiques servant a analyser des troubles de la proliferation des cellules pulmonaires et methode afferente
AU2002357968A1 (en) * 2001-12-05 2003-07-09 Epigenomics Ag Method and integrated device for the detection of cytosine methylations
US20030152950A1 (en) * 2001-06-27 2003-08-14 Garner Harold R. Identification of chemically modified polymers
DE10215770A1 (de) * 2002-04-10 2003-10-30 Michael Giesing Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits
US20040029123A1 (en) * 2000-03-15 2004-02-12 Alexander Olek Diagnosis of diseases associated with the cell cycle
US20040115630A1 (en) * 2000-06-30 2004-06-17 Alexander Olek Method and nucleic acids for the analysis of astrocytomas
US20040234960A1 (en) * 2000-09-01 2004-11-25 Alexander Olek Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029123A1 (en) * 2000-03-15 2004-02-12 Alexander Olek Diagnosis of diseases associated with the cell cycle
US20040115630A1 (en) * 2000-06-30 2004-06-17 Alexander Olek Method and nucleic acids for the analysis of astrocytomas
US20040234960A1 (en) * 2000-09-01 2004-11-25 Alexander Olek Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
US20030152950A1 (en) * 2001-06-27 2003-08-14 Garner Harold R. Identification of chemically modified polymers
WO2003014388A2 (fr) * 2001-08-09 2003-02-20 Epigenomics Ag Acides nucleiques d'analyse d'un cancer du colon et procede associe
AU2002357968A1 (en) * 2001-12-05 2003-07-09 Epigenomics Ag Method and integrated device for the detection of cytosine methylations
WO2003052135A2 (fr) * 2001-12-14 2003-06-26 Epigenomics Ag Acides nucleiques servant a analyser des troubles de la proliferation des cellules pulmonaires et methode afferente
DE10215770A1 (de) * 2002-04-10 2003-10-30 Michael Giesing Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083046A3 (fr) * 2009-01-15 2010-12-02 The Salk Institute For Biological Studies Procédés ayant recours à un séquençage de nouvelle génération pour identifier les 5-méthylcytosines dans le génome
US20110287967A1 (en) * 2009-01-28 2011-11-24 Ait Austrian Institute Of Technology Gmbh Lung Cancer Methylation Markers
WO2011028533A3 (fr) * 2009-08-24 2011-06-09 Perkinelmer Health Sciences, Inc. Procédés de détection de méthylation d'adn à l'aide de particules codées
WO2014160117A1 (fr) 2013-03-14 2014-10-02 Abbott Molecular Inc. Systèmes et procédés d'amplification multiplexe spécifiques de la méthylation
EP2971171A4 (fr) * 2013-03-14 2016-11-02 Abbott Molecular Inc Systèmes et procédés d'amplification multiplexe spécifiques de la méthylation
US9701999B2 (en) 2013-03-14 2017-07-11 Abbott Molecular, Inc. Multiplex methylation-specific amplification systems and methods
WO2015101515A3 (fr) * 2013-12-31 2015-08-20 F. Hoffmann-La Roche Ag Procédés d'évaluation de la régulation épigénétique du fonctionnement du génome par l'intermédiaire du statut de méthylation de l'adn, ainsi que systèmes et kits associés
CN106170559A (zh) * 2013-12-31 2016-11-30 豪夫迈·罗氏有限公司 经由dna甲基化状态评价基因组功能的表观遗传调节的方法以及其系统和试剂盒
JP2017501730A (ja) * 2013-12-31 2017-01-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｄｎａメチル化の状態を通してゲノム機能のエピジェネティックな調節を評価する方法ならびにそのためのシステムおよびキット
CN110923320A (zh) * 2019-12-26 2020-03-27 益善生物技术股份有限公司 用于检测肺癌相关基因甲基化的核酸组合物、试剂盒和检测方法

Similar Documents

Publication Publication Date Title
JP4216333B2 (ja) オリゴヌクレオチドの化学結合による核酸検出及び増幅
JP4420564B2 (ja) 核酸分析物における蛍光偏光
JP4527789B2 (ja) 増加した標的特異的ｔｍを持つ修飾オリゴヌクレオチドを用いた核酸配列の検出および増幅のための方法
JP3366641B2 (ja) 核酸配列を増幅し、検出するための化学的方法
US6737239B2 (en) Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents
EP0703296B1 (fr) Détermination de polynucléotides par substitution d'un brin sur une sonde de capture
JP6479474B2 (ja) 核酸ハイブリダイゼーションプローブ
JP2002537858A (ja) 核酸の配列を直接決定するための方法
JPH0292300A (ja) 選択可能な切断部位を用いたポリヌクレオチドの測定
JP2007525998A (ja) 脆弱ｘ症候群などのｓｔｒｐの検出
JPH09187275A (ja) 核酸増幅の蛍光偏光検出法
EP0146039A2 (fr) Test d'hybridation avec immobilisation d'hybrides par liaison antihybride
JP2007502126A (ja) Ｄｎａ中のシトシンのメチル化法および検出法
JP2009261406A (ja) β２アドレナリン多型検出
JP2005204652A (ja) メチル化特異的プライマー伸長（ｍｓｐｅ）によるメチル化状況を検出するアッセイ
JP2004512050A (ja) 核酸の増幅およびプロファイリングに関連する物質および方法
WO2007032748A1 (fr) Procede de detection de la methylation de l'adn
CA2687171A1 (fr) Procede d'amplification d'acide nucleique methyle ou d'acide nucleique non methyle
JPH05227998A (ja) マラリア原虫の検出
EP0610215A1 (fr) Dosage de polynucleotides a l'aide de sites de clivage pouvant etre selectionnes
JP2004521630A (ja) 変更検出のための方法
WO1999058716A1 (fr) Procede servant a quantifier une sequence specifique de genes et reactif de quantification
AU780156B2 (en) Hybridization self-recognition type probe
JPS60179657A (ja) 標識プロ−ブ及び抗−ハイブリツドを用いるハイブリツド形成分析法
JPH10179179A (ja) 特定遺伝子配列の定量方法及び定量試薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06784283

Country of ref document: EP

Kind code of ref document: A1